Fig. 4From: Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trialProportions of patients with NEDA over 2 years (baseline to Week 96): a LOCF analysis; b observed dataa. MRI, magnetic resonance imaging; NEDA, no evidence of disease activity; OR, odds ratio. aSensitivity analysis excluding patients with missing MRI dataBack to article page